Select a medication above to begin.
Sogroya (somapacitan-beco)
somapacitan
Adult Dosing .
Dosage forms: INJ (pen): 5 mg per 1.5 mL, 10 mg per 1.5 mL, 15 mg per 1.5 mL
Special Note
- [drug name clarification]
- Info: nonproprietary name = somapacitan-beco
- [strength clarification]
- Info: 5 mg per 1.5 mL pen delivers 0.025-2 mg/dose in 0.025 mg increments; 10 mg per 1.5 mL pen delivers 0.05-4 mg/dose in 0.05 mg increments; 15 mg per 1.5 mL pen delivers 0.1-8 mg/dose in 0.1 mg increments
growth hormone deficiency
- [individualize dose SC qwk]
- Start: 1.5 mg SC qwk, may incr. by 0.5-1.5 mg/dose q2-4wk; Max: 8 mg/wk; Info: adjust dose based on IGF-1 levels and symptoms; start 1 mg SC qwk and titrate in smaller increments in patients 65 yo and older
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class B: start 1 mg qwk and titrate in smaller increments, max 4 mg/wk; Child-Pugh Class C: avoid use
Peds Dosing .
- Dosage forms: INJ (pen): 5 mg per 1.5 mL, 10 mg per 1.5 mL, 15 mg per 1.5 mL
Special Note
- [drug name clarification]
- Info: nonproprietary name = somapacitan-beco
- [strength clarification]
- Info: 5 mg per 1.5 mL pen delivers 0.025-2 mg/dose in 0.025 mg increments; 10 mg per 1.5 mL pen delivers 0.05-4 mg/dose in 0.05 mg increments; 15 mg per 1.5 mL pen delivers 0.1-8 mg/dose in 0.1 mg increments
growth hormone deficiency
- [2.5 yo and older]
- Dose: 0.16 mg/kg/dose SC qwk; Info: D/C when patient reaches satisfactory ht, epiphyses close, or no response
short stature, SGA-associated
- [2.5 yo and older]
- Dose: 0.24 mg/kg/dose SC qwk; Info: for patients with no catch-up growth by 2 yo; D/C when patient reaches satisfactory ht, epiphyses close, or no response
growth failure, Noonan syndrome-associated
- [2.5 yo and older]
- Dose: 0.24 mg/kg/dose SC qwk; Info: D/C when patient reaches satisfactory ht, epiphyses close, or no response
idiopathic short stature
- [2.5 yo and older]
- Dose: 0.24 mg/kg/dose SC qwk; Info: D/C when patient reaches satisfactory ht, epiphyses close, or no response
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class B or C: avoid use
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- hypersensitivity to somatropin
- hepatic impairment, Child-Pugh Class C
- hepatic impairment, Child-Pugh Class B (peds patients)
- malignancy, active
- illness, acute critical
- respiratory failure, acute
- diabetic retinopathy
- papilledema
- epiphysis, closed (peds patients)
- obesity, severe (peds patients with Prader-Willi syndrome)
- respiratory impairment, severe (peds patients with Prader-Willi syndrome)
- upper airway obstruction (peds patients with Prader-Willi syndrome)
- sleep apnea (peds patients with Prader-Willi syndrome)
- respiratory infection (peds patients with Prader-Willi syndrome)
- caution: patients 65 yo and older
- caution: hepatic impairment, Child-Pugh Class B (adult patients)
- caution: intracranial neoplasm history
- caution: craniospinal XRT history
- caution: malignancy risk
- caution: hypopituitarism risk
- caution: hypoadrenalism
- caution: hypothyroidism
- caution: prediabetes
- caution: diabetes mellitus
- caution: obesity
- caution: scoliosis
Drug Interactions .
Overview
somapacitan
growth hormone agonist
- 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor
- affects growth hormone diagnostic test results
- hyperglycemic effects
- pseudotumor cerebri
- caution advised with drugs metabolized by CYP450 liver enzymes; growth hormone may incr. CYP450 metabolic function, decr. levels of concomitant drugs, efficacy
Avoid/Use Alternative
- macimorelin
- tretinoin
Monitor/Modify Tx
- acarbose
- acitretin
- alogliptin
- betamethasone
- bexagliflozin
- bromocriptine
- canagliflozin
- ciprofloxacin
- colesevelam
- cortisone
- cyclosporine
- cysteamine
- danazol
- dapagliflozin
- deflazacort
- delafloxacin
- demeclocycline
- dexamethasone
- doxycycline
- dulaglutide
- empagliflozin
- eravacycline
- ertugliflozin
- estetrol (contraceptive)
- estradiol (contraceptive)
- estradiol (hormone replacement)
- estrogens, conjugated (hormone replacement)
- estrogens, esterified (hormone replacement)
- ethinyl estradiol (contraceptive)
- ethinyl estradiol (hormone replacement)
- exenatide
- fludrocortisone
- glimepiride
- glipizide
- glyburide
- goserelin
- histrelin
- insulin
- isotretinoin
- leuprolide
- levofloxacin
- linagliptin
- liraglutide
- lithium
- lixisenatide
- mecasermin
- metformin
- methylprednisolone
- miglitol
- minocycline
- moxifloxacin
- nafarelin nasal
- nateglinide
- ofloxacin
- omadacycline
- palovarotene
- pioglitazone
- pramlintide
- prednisolone
- prednisone
- repaglinide
- rosiglitazone
- sarecycline
- saxagliptin
- semaglutide
- sitagliptin
- somatrogon
- somatropin
- tetracycline
- tigecycline
- tirzepatide
- triamcinolone
- triptorelin
Adverse Reactions .
Serious Reactions
- hypersensitivity reaction
- anaphylaxis
- secondary neoplasm
- diabetes mellitus
- intracranial HTN
- hypothyroidism unmasked
- hypoadrenalism unmasked
- pancreatitis
- scoliosis progression (peds patients)
- slipped capital femoral epiphysis (peds patients)
- osteonecrosis (peds patients)
- sudden death (Prader-Willi peds patients)
Common Reactions
- respiratory infection
- nasopharyngitis
- diarrhea
- fever
- cough
- ear infection (peds patients)
- headache
- vomiting
- back pain
- injection site reaction
- extremity pain
- arthralgia
- dyspepsia
- sleep disturbance
- dizziness
- tonsillitis
- peripheral edema
- adrenal insufficiency
- HTN
- CPK incr.
- weight gain
- anemia
- abdominal pain
- adenoidal hypertrophy (peds patients)
- tonsillar hypertrophy (peds patients)
- injection site lipodystrophy
- hyperphosphatemia
- alk phos incr.
Safety/Monitoring .
Monitoring Parameters
glucose, especially if diabetes or diabetes risk; TFTs; fundoscopic exam at baseline, then periodically; dermatologic exams; cortisol if hypoadrenalism
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; no human data available, though risk of infant harm not expected based on limited human data with somatropin; no known risk of teratogenicity based on animal data at 12x and 31x MRHD
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: for somapacitan: proteolytic cleavage; CYP450: none
Excretion: for somapacitan: urine 81% (none unchanged), feces 13% (none unchanged); Half-life: 2-3 days (adults), 34h (peds, 0.16 mg/kg/wk dose), 36-37h (peds, 0.24 mg/kg/wk dose)
Subclass: Growth Hormones/Agonists
Mechanism of Action
for somapacitan: binds to growth hormone receptor, stimulating multiple growth, anabolic, and anti-catabolic effects (growth hormone analog)
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.